Trivitron Healthcare looks to raise upto $50 mn through PE route

Last year the company got commitments of $75 million anchored by Fidelity Growth Partners India

Raghuvir Badrinath Bangalore
Last Updated : Sep 05 2013 | 2:41 PM IST
Trivitron Healthcare, the Chennai-based medical devices manufacturer, is looking to raise anywhere between $30-$50 million through the private equity route in the near future.

This move by Trivitron Healthcare to raise additional funds comes hardly with a year after it got commitments of $75 million anchored by Fidelity Growth Partners India. Trivitron, prior to Fidelity, had raised funds from ePlanet Ventures and Headland Capital, who partially exited during the last round.

Trivitron, which posted revenues of Rs 600 crore for the last fiscal, has been expanding rapidly in various geographies and has drawn out a blue-print to have a strong presence in the imaging and lab diagnostics segments through organic growth as well as through acquisition of companies and technologies in Europe and the United States. The management of Trivitron said that their Board of Directors is not considering fresh fund raise as of now.

In addition to expanding its presence at global locations, the fresh inflow of funds will also be used to an extent for the Trivitron Medical Technology Park, a 25-acre manufacturing facility in Chennai and which is mapped to house over 15 different medical technology manufacturing facilities of Trivitron’s subsidiaries and joint ventures.

Trivitron’s joint ventures with Hitachi-Aloka (Japan) for manufacturing ultrasound equipment and with Biosystems (Spain) for lab diagnostics reagents are already operational. The company has recently set up centres of innovation for biomedical equipment in collaboration with the Indian Institute of Technology (IIT), Madras and under the leadership of its Director (R&D), Prof. Bhuvaneshwar, a well recognized innovator in this area.

Trivitron was founded in 1997 by Dr G S K Velu after his stint as the Country Head for Chiron Diagnostics, before embarking on an entrepreneurial journey. In addition to Trivitron, Dr Velu has co-founded and built a pan-India path lab chain, Metropolis Healthcare, as well as Medfort, a chain of single specialty, eye-care and diabetes-care hospitals.

He has also co-founded a joint venture with the Apollo Hospitals Group for dental clinics(Apollo White) and dialysis centres (Apollo Dialysis).

This move by Trivitron to raise fresh funds comes at a time when many more private equity fund are looking to invest in the entire value of healthcare chain. The healthcare and life sciences sector witnessed a 66% growth in the value of investments, seeing an increase from $130 million in Q1 of 2013 to $215 million in Q2 of 2013, according to data from PwC.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 05 2013 | 2:39 PM IST

Next Story